Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

CorMedix (CRMD) Equity Average: 2012-2025

Historic Equity Average for CorMedix (CRMD) over the last 10 years, with Sep 2025 value amounting to $297.4 million.

  • CorMedix's Equity Average rose 467.00% to $297.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $297.4 million, marking a year-over-year increase of 467.00%. This contributed to the annual value of $58.9 million for FY2022, which is 10.13% up from last year.
  • According to the latest figures from Q3 2025, CorMedix's Equity Average is $297.4 million, which was up 77.27% from $167.8 million recorded in Q2 2025.
  • In the past 5 years, CorMedix's Equity Average registered a high of $297.4 million during Q3 2025, and its lowest value of $51.5 million during Q2 2023.
  • Its 3-year average for Equity Average is $98.4 million, with a median of $68.4 million in 2023.
  • In the last 5 years, CorMedix's Equity Average declined by 22.63% in 2022 and then surged by 467.00% in 2025.
  • CorMedix's Equity Average (Quarterly) stood at $66.1 million in 2021, then declined by 15.72% to $55.7 million in 2022, then climbed by 12.03% to $66.1 million in 2023, then declined by 20.69% to $71.7 million in 2024, then surged by 467.00% to $297.4 million in 2025.
  • Its Equity Average stands at $297.4 million for Q3 2025, versus $167.8 million for Q2 2025 and $99.8 million for Q1 2025.